CVS Health director Larry Robbins disclosed a large open-market sale on May 19, 2026, unloading 1,983,387 shares at $94.45 each for about $187.33 million. By dollar value and share count, this is a notable insider transaction and stands out as the only reported insider trade at CVS in the past 30 days. As a director, Robbins is part of the board that oversees strategy and management performance, so investors often watch his transactions as a signal of how a key overseer is positioning personally. A sale of this size can reflect many non-business reasons (such as portfolio rebalancing, taxes, or diversification), but it still matters because it represents a meaningful reduction in exposure at a single point in time. The timing is also worth noting: the sale came shortly after smaller insider purchases reported on May 14, 2026, at a higher price of $97.15 per share. That contrast doesn’t prove a unified “insider view,” since different insiders can act for different reasons, but it does highlight mixed recent activity around similar price levels. Investors may want to monitor upcoming filings for any additional board or executive trades that confirm whether this was a one-off event or part of a broader pattern.